Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Current Liabilities: 2015-2024

Historic Total Current Liabilities for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $23.0 million.

  • Cartesian Therapeutics' Total Current Liabilities fell 35.52% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 35.52%. This contributed to the annual value of $23.0 million for FY2024, which is 66.32% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Total Current Liabilities stood at $23.0 million for FY2024, which was down 66.32% from $68.2 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Total Current Liabilities high stood at $81.5 million for FY2020, and its period low was $23.0 million during FY2024.
  • Over the past 3 years, Cartesian Therapeutics' median Total Current Liabilities value was $25.1 million (recorded in 2022), while the average stood at $38.8 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Total Current Liabilities surged by 172.00% in 2023, and later crashed by 66.32% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Total Current Liabilities (Yearly) stood at $81.5 million in 2020, then fell by 11.40% to $72.3 million in 2021, then crashed by 65.29% to $25.1 million in 2022, then soared by 172.00% to $68.2 million in 2023, then tumbled by 66.32% to $23.0 million in 2024.